Glass House Brands Applauds Cannabis Reform Action

Core Viewpoint - The recent executive order from the Trump administration to reschedule cannabis to a Schedule III classification and authorize a pilot program for Medicare reimbursement of CBD is seen as a significant drug reform, enhancing access to cannabis for medical purposes [2][3]. Company Overview - Glass House Brands Inc. is recognized as one of the fastest-growing, vertically integrated cannabis companies in the U.S., focusing on the California market and building strong brands across various consumer segments [4]. Market Opportunities - The rescheduling of cannabis is expected to create export opportunities into international markets, with Glass House positioned to capitalize on the growth of the U.S. CBD market [3]. - The Medicare reimbursement program will allow over 60 million seniors to receive $500 per year for CBD, creating a market exceeding $30 billion [3]. Production and Development - Glass House has a low-cost, high-quality cannabinoid production model and is prepared to be a leading supplier in the emerging CBD market [3]. - The company is actively developing CBD products in compliance with new federal regulations and is collaborating with the University of California Berkeley on hemp research [3]. Operational Readiness - The company has ramped up its cultivation efforts, achieving the most acreage planted in its history, and plans to continue expanding in early 2026 [3].